Areas of Focus
- Tumor biology and molecular targeted therapy
- Tumor resistance mechanisms and drug combination strategies
Work Experience
- 2022-01 to present - Professor, School of Life Sciences, East China Normal University
- 2018-12 to 2021-12 - Researcher, School of Life Sciences, East China Normal University
- 2015-09 to 2016-09 - Visiting Scholar, National Cancer Institute, NIH, USA
- 2012-07 to 2018-12 - Associate Researcher, School of Life Sciences, East China Normal University
- 2009-07 to 2012-07 - Lecturer, School of Life Sciences, East China Normal University
Academic Background & Achievements
- 2007-10 to 2009-10 - PhD in Tumor and Stem Cell Biology, Texas A&M University Health Science Center, USA (Joint Training)
- 2004-09 to 2009-06 - PhD in Biomedical Science, East China Normal University
- 2000-09 to 2004-06 - Bachelor in Biotechnology, East China Normal University
Publications
- Design, synthesis and pharmacological evaluation of multisubstituted pyrido[4,3-d]pyrimidine analogues bearing deuterated methylene linkers as potent KRASG12D inhibitors, Xiao X, Feng J, Ma J, Xia X, Liu X, Zhang J, Ding C, Pang X*, Zhang A*, 2023
- Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons, Liu Y, Hu L, Wu Z, Yuan K, Hong G, Lian Z, Feng J, Li N, Li D, Wong J, Chen J, Liu M, He J*, Pang X*, 2023
- Discovery of a potent and oral complex I OXPHOS inhibitor that abrogates tumor growth and circumvents MEKi resistance, He P, Feng J, Xia X, Sun Y, He J, Guan T, Peng Y, Zhang X, Liu M, Pang X*, Chen Y*, 2023
- Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer, Feng J, Hu Z, Xia X, Liu X, Lian Z, Wang H, Wang L, Wang C, Zhang X*, Pang X*, 2023
- Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer, Feng J, Lian Z, Xia X, Lu Y, Hu K, Zhang Y, Liu Y, Hu L, Yuan K, Sun Z*, Pang X*, 2023
- BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer, Li K, Liu Y, Ding Y, Zhang Z, Feng J, Hu J, Chen J, Lian Z, Chen Y, Hu K, Chen Z, Cai Z, Liu M, Pang X*, 2022
- The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress, Liu Y, Feng J, Yuan K, Wu Z, Hu L, Lu Y, Li K, Guo J, Chen J, Ma C*, Pang X*, 2022
- Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitor, Jiang B, Hu J, Liu H, Liu Z, Wen Y, Liu M, Zhang H, Pang X*, Yu L*, 2022
- BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors, Guo J, Liu Y, Lv J, Zou B, Chen Z, Li K, Feng J, Cai Z, Wei L, Liu M, Pang X*, 2021
- Blocking STAT3 by Pyrvinium Pamoate Causes Metabolic Lethality in KRAS-mutant Lung Cancer, Feng J, Jiang W, Liu Y, Huang W, Hu K, Li K, Chen J, Ma C*, Sun Z*, Pang X*, 2020
- Suppression of the SLC7A11/glutathione Axis Causes Synthetic Lethality in KRAS-mutant Lung Adenocarcinoma, Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao PJ, Cai Z, Chen Y*, Liu M*, Pang X*, 2020
- Repurposing Sertraline Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib by Inducing Autophagy, Jiang X, Lu W, Shen X, Wang Q, Lv J, Liu M, Cheng F*, Zhao Z*, Pang X*, 2018
- Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo, Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X*, 2017
- Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK, Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X*, Liu M*, 2016
Awards
- 2021: Recipient of the National Natural Science Foundation of China Excellent Young Scientists Fund
- 2020: Selected for the Shanghai Municipal Universities Special Professor Plan
- 2018: Selected for the Shanghai Pujiang Talent Plan
- 2016: Selected as one of China's Top Ten Emerging Sci-Tech Personalities
- 2010: Selected for the Shanghai Municipal Education Commission's Morning Light Scholar Plan
